© 1999 Oxford University Press
Article |
-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro
Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE and
1 MRC Toxicology Unit, Hodgkin Building, Lancaster Road, Leicester LE1 9HN, UK
The metabolic formation of 
-hydroxytamoxifen, a reactive metabolite of tamoxifen in rat liver, was characterized and quantified in vitro (hepatic microsomal incubations) and in vivo (bile-duct cannulated animals). This minor metabolite was identified by chromatographic and mass spectral comparisons with the authentic compound. The rates of formation of -hydroxytamoxifen in incubations (30 min) of tamoxifen (25 µM) with liver microsomal preparations from women (pool of six), female CD1 mice or female Sprague–Dawley rats, as quantified by liquid chromatography–mass spectrometry (LC–MS), were 1.15 ± 0.03, 0.30 ± 0.05 and 2.70 ± 0.35 pmol/min/mg protein, respectively. Selective inhibition of microsomal P450 indicated that -hydroxylation was catalysed predominantly by CYP3A in humans. Bile-duct cannulated and anaesthetized female rats and mice given [14C]tamoxifen (43 µmol/kg, i.v.) excreted, respectively, 24 and 21% of the administered radioactivity in bile over 5 and 3.5 h. The major radiolabelled biliary metabolite in rats, characterized by LC–MS after enzymic hydrolysis of conjugates, was the glucuronide of 4-hydroxytamoxifen (10% of dose) and only 0.1% of the dose was recovered as -hydroxytamoxifen. After administration of -hydroxytamoxifen (43 µmol/kg, i.v.) to rats, only 1.19% of the administered compound was recovered from a glucuronide metabolite in bile, indicating a possible 0.84% -hydroxylation of tamoxifen in vivo. There was, however, no indication of the presence in bile of either O-sulphonate or glutathione conjugates derived from -hydroxytamoxifen. This study shows for the first time that -hydroxytamoxifen can be glucuronylated in rat liver. Whereas sulphonation results in electrophilic genotoxic intermediates, glucuronidation may represent a means of detoxifying -hydroxytamoxifen.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, J. Yan, R. Lubet, T. W. Kensler, and T. R. Sutter Identification of novel transcriptional networks in response to treatment with the anticarcinogen 3H-1,2-dithiole-3-thione Physiol Genomics, January 12, 2006; 24(2): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Boocock, K. Brown, A. H. Gibbs, E. Sanchez, K. W. Turteltaub, and I. N.H. White Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA Carcinogenesis, November 1, 2002; 23(11): 1897 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats Carcinogenesis, March 1, 2002; 23(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White, P. Carthew, R. Davies, J. Styles, K. Brown, J. E. Brown, L. L. Smith, and E. A. Martin Short-term dosing of {{alpha}}-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats Carcinogenesis, April 1, 2001; 22(4): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N.H. White The tamoxifen dilemma Carcinogenesis, July 1, 1999; 20(7): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|